PARP1 and ovarian carcinoma: The PARP‐ATR inhibitor combination caused the complete regression of BRCA‐mutated ovarian cancer PDX tumours, while the PARP‐CHK1 inhibitor combination led only to tumour suppression rather than to tumour regression.